Análise epidemiológica da pandemia de SARS-Cov2 na população mexicana; avaliação intermediária, características, comorbidade e risco.
Palavras-chave:
COVID - 19, SARS-Cov2, Epidemiologia, México, InfecçãoResumo
Considerando a relevância epidemiológica da documentação da pandemia de SARS-Cov2 no México, é realizado um primeiro exercício de avaliação e análise considerado pela metade, o que confirma um espectro de características com a referência mundial que a precedeu, mas enfatiza em condições de extrema importância para o país, como o amplo e conhecido risco que a população tem em relação a doenças metabólicas e cardiovasculares crônicas; bem como um ambiente coletivo no qual a doença chegaria, com uma população em trânsito de um regime político, às ações de modificação estrutural propostas, bem como à conhecida deterioração de instituições públicas, incluindo o sistema nacional de saúde. Apresentam-se resultados da análise epidemiológica, na qual se destaca o aumento do risco em homens e de acordo com um gradiente de idade, o que corresponde a maiores condições de gravidade e morte. Independentemente, diabetes mellitus, hipertensão, doença renal crônica e imunossupressão, bem como indicadores de controle diante da gravidade, estabelecem a necessidade abrangente de abordagens mais amplas, bem como a incursão em avaliações vinculadas ao ambiente coletivo da população mexicana.
Downloads
Referências
1. WHO | Pneumonia of unknown cause – China. WHO. 2020; https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/ (Acceso 15/06/2020)
2. Bagcchi S. Mysterious pneumonia in China. Lancet Infect Dis. 2020 Feb 1;20(2):173.
3. Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Vol. 63, Science China Life Sciences. Science in China Press; 2020. p. 457–60.
4. Cortés ME. Coronavirus como amenaza a la salud pública. Rev Med Chil [Internet]. 2020 Jan [cited 2020 Jun 15];148(1):124–6. Available from: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000100124&lng=en&nrm=iso&tlng=en
5. Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm. Vol. 50, European Journal of Clinical Investigation. Blackwell Publishing Ltd; 2020.
6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054–62.
7. Zhang N, Wang L, Deng X, Liang R, Su M, He C, et al. Recent advances in the detection of respiratory virus infection in humans. Vol. 92, Journal of Medical Virology. John Wiley and Sons Inc.; 2020. p. 408–17.
8. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020 Mar 12;579(7798):265–9.
9. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar 12;579(7798):270–3.
10. Wu Y-C, Chen C-S, Chan Y-J. The outbreak of COVID-19: An overview. J Chinese Med Assoc [Internet]. 2020 [cited 2020 Jun 15];83:217–20. Available from: www.ejcma.org
11. Loades ME, Chatburn E, Higson-Sweeney N, Reynolds S, Shafran R, Brigden A, et al. Rapid Systematic Review: The Impact of Social Isolation and Loneliness on the Mental Health of Children and Adolescents in the Context of COVID-19. J Am Acad Child Adolesc Psychiatry [Internet]. 2020 Jun 3 [cited 2020 Jun 15]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32504808
12. Crespo RM, Morales Crespo MM. Pandemia COVID-19, la nueva emergencia sanitaria de preocupación internacional: una revisión. Med Fam Semer. 2020 May;
13. Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, a worldwide public health emergency. Revista Clinica Espanola. Elsevier Doyma; 2020.
14. Khan Z, Karataş Y, Fahriye Ceylan A, Rahman H. COVID-19 and therapeutic drugs repurposing in hand: the need for collaborative efforts. Le Pharm Hosp Clin [Internet]. 2020 Jun [cited 2020 Jun 15]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S2211104220300795
15. Chiappelli F. Volume 16(2) Editorial 2019-nCoV-Towards a 4 th generation vaccine. Bioinformation [Internet]. 2020 [cited 2020 Jun 15];16(2):139–44. Available from: www.bioinformation.net
16. Bhagavathula AS, Aldhaleei WA, Rovetta A, Rahmani J. Vaccines and Drug Therapeutics to Lock Down Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review of Clinical Trials. Cureus [Internet]. 2020 May 28 [cited 2020 Jun 15];12(5):e8342. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32494546
17. Fernandes EG, Da J, Santos S, Keico H, Iii S. Outbreak investigation in cargo ship in times of COVID-19 crisis, Port of Santos, Brazil. 2020 [cited 2020 Jun 15]; Available from: http://doi.org/10.11606/s1518-8787.2020054002461
18. Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, Méndez CA, Zambrano LI, Franco-Paredes C, et al. COVID-19 in Latin America: The implications of the first confirmed case in Brazil. Travel Medicine and Infectious Disease. Elsevier USA; 2020.
19. Amariles P, Granados J, Ceballos M, Montoya CJ. COVID-19 in Colombia endpoints. Are we different, like Europe? Res Soc Adm Pharm. 2020;
20. Skums P, Kirpich A, Baykal PI, Zelikovsky A, Chowell G. Global transmission network of SARS-CoV-2: from outbreak to pandemic. medRxiv. 2020;2020.03.22.20041145.
21. Gemelli NA. Management of COVID-19 Outbreak in Argentina: The Beginning. Disaster Med Public Health Prep. 2020;1.
22. Suárez V, Suarez Quezada M, Oros Ruiz S, Ronquillo De Jesús E. Epidemiología de COVID-19 en México: del 27 febrero al 30 de abril de 2020. Rev Clínica Española [Internet]. 2020 May [cited 2020 Jun 15]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0014256520301442
23. Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020 Apr 1;55(4):105946.
24. Torrealba-Rodriguez O, Conde-Gutiérrez RA, Hernández-Javier AL. Modeling and prediction of COVID-19 in Mexico applying mathematical and computational models. Chaos, Solitons and Fractals. 2020 Sep 1;138.
25. COVID-19 Tablero México - CONACYT - CentroGeo - GeoInt - DataLab [Internet]. [cited 2020 Jun 15]. Available from: https://coronavirus.gob.mx/datos/
26. Chiappetta S, Sharma AM, Bottino V, Stier C. COVID-19 and the role of chronic inflammation in patients with obesity. Int J Obes. 2020 May 14;1–3.
27. Martínez-Anaya C, Ramos-Cervantes P, Vidaltamayo R. Coronavirus, diagnóstico y estrategias epidemiológicas contra COVID-19 en México. Educ Química. 2020 Apr 15;31(2):12.
28. Cordera R, Provencio E. Cambiar el rumbo: el desarrollo tras la pandemia [Internet]. 2020 [cited 2020 Jun 17]. Available from: http://www.nuevocursodedesarrollo.unam.mx/docs/GNCD_Cambiarelrumbo.pdf#page=103
29. Datos Abiertos - Dirección General de Epidemiología | Secretaría de Salud | Gobierno | gob.mx [Internet]. [cited 2020 Jun 15]. Available from: https://www.gob.mx/salud/documentos/datos-abiertos-152127
30. PROYECCIÓN PRELIMINAR DEL CORONAVIRUS (COVID-19) PARA MÉXICO [Internet]. [cited 2020 Jun 15]. Available from: https://www.researchgate.net/publication/340032649_PROYECCION_PRELIMINAR_DEL_CORONAVIRUS_COVID-19_PARA_MEXICO
31. Gabutti G, d’Anchera E, Sandri F, Savio M, Stefanati A. Coronavirus: Update Related to the Current Outbreak of COVID-19. Vol. 9, Infectious Diseases and Therapy. Adis; 2020.
32. Ekiz T, Pazarlı AC. Relationship between COVID-19 and obesity. Diabetes Metab Syndr Clin Res Rev. 2020 Sep 1;14(5):761–3.
33. Jain V, Yuan J-M. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health [Internet]. 2020 May 25 [cited 2020 Jun 15];1. Available from: http://link.springer.com/10.1007/s00038-020-01390-7
34. Chen L, Yu J, He W, Chen L, Yuan G, Dong F, et al. Risk factors for death in 1859 subjects with COVID-19. [cited 2020 Jun 17]; Available from: https://doi.org/10.1038/s41375-020-0911-0
35. Agudelo-Botero M, Valdez-Ortiz R, Giraldo-Rodríguez L, González-Robledo MC, Mino-León D, Rosales-Herrera MF, et al. Overview of the burden of chronic kidney disease in Mexico: Secondary data analysis based on the Global Burden of Disease Study 2017. BMJ Open. 2020 Mar 25;10(3):e035285.
36. Wyper GMA, Assunção R, Cuschieri S, Devleeschauwer B, Fletcher E, Haagsma JA, et al. Population vulnerability to COVID-19 in Europe: a burden of disease analysis. Arch Public Heal [Internet]. 2020 Dec 29 [cited 2020 Jun 15];78(1):47. Available from: https://archpublichealth.biomedcentral.com/articles/10.1186/s13690-020-00433-y
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2020 Escuela de Salud Pública y Ambiente. Facultad de Ciencias Médicas. Universidad Nacional de Córdoba
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional. que permite copiar, distribuir, exhibir e interpretar la obra siempre que no se haga con fines comerciales.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) luego del proceso de publicación. (Véase El efecto del acceso abierto).
